ES2186886T3 - Proteinas solubles. - Google Patents

Proteinas solubles.

Info

Publication number
ES2186886T3
ES2186886T3 ES97918634T ES97918634T ES2186886T3 ES 2186886 T3 ES2186886 T3 ES 2186886T3 ES 97918634 T ES97918634 T ES 97918634T ES 97918634 T ES97918634 T ES 97918634T ES 2186886 T3 ES2186886 T3 ES 2186886T3
Authority
ES
Spain
Prior art keywords
protein
native protein
proteins
soluble
native
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97918634T
Other languages
English (en)
Inventor
Stanley B Prusiner
Fred E Cohen
Tamaki Muramoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Application granted granted Critical
Publication of ES2186886T3 publication Critical patent/ES2186886T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Non-Silver Salt Photosensitive Materials And Non-Silver Salt Photography (AREA)
  • Bipolar Transistors (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Detergent Compositions (AREA)

Abstract

Proteína PrPsc modificada que se caracteriza por: a) comprender menos aminoácidos que una proteína PrPs° nativa; b) causar una enfermedad priónica cuando se inocula un animal con la proteína soluble; y c) ser por lo menos dos veces más soluble que la proteína PrPs° nativa en una solución acuosa, ausencia de un detergente desnaturalizante.
ES97918634T 1996-11-05 1997-04-15 Proteinas solubles. Expired - Lifetime ES2186886T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/740,947 US5834593A (en) 1996-11-05 1996-11-05 Soluble form of PrPSC which is insoluble in native form

Publications (1)

Publication Number Publication Date
ES2186886T3 true ES2186886T3 (es) 2003-05-16

Family

ID=24978724

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97918634T Expired - Lifetime ES2186886T3 (es) 1996-11-05 1997-04-15 Proteinas solubles.

Country Status (13)

Country Link
US (1) US5834593A (es)
EP (1) EP1012162B1 (es)
JP (1) JP2001506979A (es)
AT (1) ATE227736T1 (es)
AU (1) AU720533B2 (es)
BR (1) BR9712874A (es)
CA (1) CA2268354A1 (es)
DE (1) DE69717167T2 (es)
DK (1) DK1012162T3 (es)
ES (1) ES2186886T3 (es)
NZ (1) NZ335103A (es)
PT (1) PT1012162E (es)
WO (1) WO1998020022A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2758337B1 (fr) * 1997-01-14 1999-03-05 Commissariat Energie Atomique Methode de criblage de substances a action therapeutique dans le traitement des esst comprenant une etape d'isolement de la prpres, a partir de la rate, procede d'isolement de le prpres et ses applications
GB2348203B (en) 1998-11-04 2002-06-19 Imp College Innovations Ltd Solube beta-forms of prion proteins, methods of preparation and use
US6166187A (en) * 1999-03-05 2000-12-26 The Regents Of The University Of California Method of concentrating prion proteins in blood samples
DE19918141A1 (de) * 1999-04-21 2000-10-26 Boehringer Ingelheim Vetmed Verfahren zur Diagnose von übertragbaren Spongiformen Enzephalopathien
US6437102B1 (en) 1999-11-24 2002-08-20 Bayer Corporation Method of separating prions from biological materials
AU2002258646A1 (en) * 2001-03-30 2002-10-15 Texas A And M University System Transgenic animals resistant to transmissible spongiform encephalopathies
GB0419628D0 (en) * 2004-09-03 2004-10-06 European Molecular Biology Lab Embl Method for determining protein solubility

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013720A (en) * 1986-05-06 1991-05-07 Abbott Laboratories SAP-6-Val proteins and methods
US5266684A (en) * 1988-05-02 1993-11-30 The Reagents Of The University Of California Peptide mixtures
EP0483247A4 (en) * 1989-07-21 1992-12-09 Washington University Recombinantly produced human membrane cofactor protein (mcp)
US5182366A (en) * 1990-05-15 1993-01-26 Huebner Verena D Controlled synthesis of peptide mixtures using mixed resins
ES2237747T3 (es) * 1991-11-14 2005-08-01 Prionics Ag Animales transgenicos no humanos que carecen de proteinas prionicas.
AU4376093A (en) * 1992-05-15 1993-12-13 Instituto Nazionale Neurologico C. Besta Soluble prion polypeptides, and methods for detecting and purifying thereof
US5605691A (en) * 1992-09-17 1997-02-25 Ophidian Pharmaceuticals, Inc. Immunologically active proteins from inclusion bodies
US5565186A (en) * 1994-05-13 1996-10-15 The Regents Of The University Of California Method of detecting prions in a sample and transgenic animal used for same

Also Published As

Publication number Publication date
EP1012162B1 (en) 2002-11-13
BR9712874A (pt) 2000-02-01
EP1012162A1 (en) 2000-06-28
AU2669497A (en) 1998-05-29
DE69717167T2 (de) 2003-07-24
PT1012162E (pt) 2003-04-30
WO1998020022A1 (en) 1998-05-14
US5834593A (en) 1998-11-10
ATE227736T1 (de) 2002-11-15
NZ335103A (en) 2000-10-27
EP1012162A4 (en) 2000-06-28
DE69717167D1 (de) 2002-12-19
CA2268354A1 (en) 1998-05-14
AU720533B2 (en) 2000-06-01
JP2001506979A (ja) 2001-05-29
DK1012162T3 (da) 2003-03-10

Similar Documents

Publication Publication Date Title
Kang et al. Characterization of the cyanogen bromide peptides from the α1 chain of chick skin collagen
AR000610A1 (es) Un método para la expresión de un polipéptido recombinante por una célula huésped
ATE96447T1 (de) Verfahren zur isolierung basischer proteine aus proteingemischen.
ATE367398T1 (de) Verfahren zur rückfaltung von proteinen mit freien cysteinresten
ME00184B (me) Osteoprotegerin vezujući proteini i receptori
DK1005540T3 (da) IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
EA200000109A1 (ru) Химерный белок растворимого рецептора интерлейкина-6/лиганда, его аналоги и способы применения
Tuross et al. [9] Ancient proteins in fossil bones
DK1218504T3 (da) GL50 molekyler og anvendelser deraf
BR122013003013B8 (pt) proteína isolada monopeguilada do hormônio do crescimento e método para sua obtenção
WO2001073059A3 (en) 38692 and 21117: dual specificity phosphatase molecules and uses therefor
Mortarino et al. Two‐dimensional polyacrylamide gel electrophoresis map of bull seminal plasma proteins
DE602006017667D1 (de) Cysteinhaltiges peptid-tag zur stellenspezifischen konjugation von proteinen
ATE419358T1 (de) Gebrauchsverfaheren eines neuen lysyloxidase- verwandten proteins
ES2186886T3 (es) Proteinas solubles.
DE68925275T2 (de) Endotoxin-bindeprotein und dessen verwendung
FR2816410B1 (fr) Necessaire de detection de la proteine esm-1 et procede de detection mettant en oeuvre ledit necessaire
Fawell et al. Androgen-regulated proteins of rat seminal vesicle secretion constitute a structurally related family present in the copulatory plug
Yoshiya et al. Development of trityl group anchored solubilizing tags for peptide and protein synthesis
DE69028711D1 (de) Verfahren zur proteinreinigung
ATE470716T1 (de) 18480 humane proteinkinasemoleküle und ihre verwendungen
WO2001092495A3 (en) A human lysyl ixodase (47765) and uses thereof
Colpitts et al. Mammaglobin complexes with BU101 in breast tissue
WO1999055885A3 (en) Novel serine protease capable of selective cleavage of insulin-like growth factor binding protein
Prisby et al. Wheat-Based Glues in Conservation and Cultural Heritage:(Dis) solving the Proteome of Flour and Starch Pastes and Their Adhering Properties